Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Beats on EPS, Stock Up 6.76%

Corvus Pharmaceuticals reported a narrower-than-expected loss per share, which contributed to a positive stock reaction of 6.76%. However, without revenue figures or management commentary, it's difficult to assess the overall performance and future outlook. Investors may view the EPS beat as a sign of improved financial health, but the lack of additional information leaves some uncertainty.